Related references
Note: Only part of the references are listed.Targeting the NKG2D/NKG2D-L axis in acute myeloid leukemia
Zhenhui Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
Ahmad I. Antar et al.
LEUKEMIA (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
Quizartinib for the treatment of acute myeloid leukemia
Alejandro Garcia-Horton et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
Cesar Sommer et al.
MOLECULAR THERAPY (2020)
Nonclinical Safety Assessment of AMG 553, an Investigational Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Acute Myeloid Leukemia
Christine Karbowski et al.
TOXICOLOGICAL SCIENCES (2020)
Chimeric antigen receptor T cell therapies for acute myeloid leukemia
Bin Gu et al.
FRONTIERS OF MEDICINE (2020)
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia
Christine M. McMahon et al.
CANCER DISCOVERY (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib
Hardikkumar Jetani et al.
LEUKEMIA (2018)
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor
Lauren Y. Lee et al.
BLOOD (2017)
Sunitinib Induces NK-κB- dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells
Yu-xian Huang et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia
L. Chen et al.
LEUKEMIA (2017)
FLT3-ITD and its current role in acute myeloid leukaemia
Francisco Alejandro Lagunas-Rangel et al.
MEDICAL ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma
Sarah Nikiforow et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Alfred L. Garfall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
Xiaochuan Yang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Weiguo Zhang et al.
CLINICAL CANCER RESEARCH (2014)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
Prognostic Value of FLT3 Mutations Among Different Cytogenetic Subgroups in Acute Myeloid Leukemia
Fabio P. S. Santos et al.
CANCER (2011)
Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2
Hai Li et al.
CELL CYCLE (2011)
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2
Yuxian Huang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
Farhad Ravandi et al.
LEUKEMIA RESEARCH (2010)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
NKG2D ligands in tumor immunity
N. Nausch et al.
ONCOGENE (2008)
Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways
Obdulio Piloto et al.
BLOOD (2007)
A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy
Steven Knapper et al.
BLOOD (2006)
Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth
B Williams et al.
LEUKEMIA (2005)
NF-kB regulates expression of the MHC class I-related chain A gene-in activated T lymphocytes
LL Molinero et al.
JOURNAL OF IMMUNOLOGY (2004)
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
HR Salih et al.
BLOOD (2003)
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
R Grundler et al.
BLOOD (2003)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
FM Abu-Duhier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
M Mizuki et al.
BLOOD (2000)
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
F Hayakawa et al.
ONCOGENE (2000)
Share Paper
